138 related articles for article (PubMed ID: 12715168)
21. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
22. [The significance of lymph node status in papillary and follicular thyroid gland carcinoma for the nuclear medicine physician].
Farahati J; Mörtl M; Reiners C
Zentralbl Chir; 2000; 125(10):830-4. PubMed ID: 11098578
[TBL] [Abstract][Full Text] [Related]
23. Expression of HER2/neu in primary and metastatic breast cancer.
Tuziak T; Olszewski WP; Olszewski W; Pieńkowski T
Pol J Pathol; 2001; 52(1-2):21-6. PubMed ID: 11505677
[TBL] [Abstract][Full Text] [Related]
24. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases.
Belfiore A; Gangemi P; Costantino A; Russo G; Santonocito GM; Ippolito O; Di Renzo MF; Comoglio P; Fiumara A; Vigneri R
J Clin Endocrinol Metab; 1997 Jul; 82(7):2322-8. PubMed ID: 9215314
[TBL] [Abstract][Full Text] [Related]
25. Papillary and follicular thyroid carcinomas with bone metastases: a series of 39 cases during a period of 18 years.
Fanchiang JK; Lin JD; Huang MJ; Shih HN
Changgeng Yi Xue Za Zhi; 1998 Dec; 21(4):377-82. PubMed ID: 10074721
[TBL] [Abstract][Full Text] [Related]
26. The Precursor for Nerve Growth Factor (proNGF) in Thyroid Cancer Lymph Node Metastases: Correlation with Primary Tumour and Pathological Variables.
Rowe CW; Dill T; Faulkner S; Gedye C; Paul JW; Tolosa JM; Jones M; King S; Smith R; Hondermarck H
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31775361
[TBL] [Abstract][Full Text] [Related]
27. HER-2÷neu expression in different histological subtypes of papillary thyroid carcinoma.
Ciobanu Apostol D; Căruntu ID; Lozneanu L; Andriescu EC; Giuşcă SE
Rom J Morphol Embryol; 2017; 58(2):439-444. PubMed ID: 28730228
[TBL] [Abstract][Full Text] [Related]
28. Clinical presentations and predictive variables of thyroid microcarcinoma with distant metastasis.
Lin KD; Lin JD; Huang MJ; Huang HS; Jeng LB; Chao TC; Ho YS
Int Surg; 1997; 82(4):378-81. PubMed ID: 9412835
[TBL] [Abstract][Full Text] [Related]
29. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas.
Scheumman GF; Hoang-Vu C; Cetin Y; Gimm O; Behrends J; von Wasielewski R; Georgii A; Birchmeier W; von Zur Mühlen A; Dralle H
J Clin Endocrinol Metab; 1995 Jul; 80(7):2168-72. PubMed ID: 7608273
[TBL] [Abstract][Full Text] [Related]
31. Expression of c-erbB-2 protein in papillary thyroid carcinomas.
Haugen DR; Akslen LA; Varhaug JE; Lillehaug JR
Br J Cancer; 1992 Jun; 65(6):832-7. PubMed ID: 1352125
[TBL] [Abstract][Full Text] [Related]
32. EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases.
Ensinger C; Kremser R; Prommegger R; Spizzo G; Schmid KW
J Immunother; 2006; 29(5):569-73. PubMed ID: 16971812
[TBL] [Abstract][Full Text] [Related]
33. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
34. Estrogen-receptor protein in thyroid neoplasms. An immunohistochemical analysis of papillary carcinoma, follicular carcinoma, and follicular adenoma.
Diaz NM; Mazoujian G; Wick MR
Arch Pathol Lab Med; 1991 Dec; 115(12):1203-7. PubMed ID: 1768209
[TBL] [Abstract][Full Text] [Related]
35. Preferential reduction of nm23-H1 gene product in metastatic tissues from papillary and follicular carcinomas of the thyroid.
Arai T; Yamashita T; Urano T; Masunaga A; Itoyama S; Itoh K; Shiku H; Sugawara I
Mod Pathol; 1995 Apr; 8(3):252-6. PubMed ID: 7617649
[TBL] [Abstract][Full Text] [Related]
36. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
37. The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium.
Ratcliffe N; Wells W; Wheeler K; Memoli V
Mod Pathol; 1997 Dec; 10(12):1247-52. PubMed ID: 9436971
[TBL] [Abstract][Full Text] [Related]
38. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
39. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
40. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
